Navigation Links
Anthera Announces First Quarter 2012 Financial Report and Conference Call
Date:4/27/2012

HAYWARD, Calif., April 27, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, will release its first quarter 2012 financial report after market close on Thursday, May 3, 2012. Anthera will host a conference call at 8:30 am Eastern Time on Friday, May 4, 2012.

Conference Call Access:
Date: Friday, May 4, 2012
Time: 8:30 am Eastern Time

Domestic Dial-in: (877) 312-8807
International Dial-in: (253) 237-1190
Conference ID: 76225935

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406. The conference ID for the replay is 76225935. The audio replay will be available until May 11, 2012. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Blood Test for DepressionSAN DIEGO, April 23 ... commercializing its first-in-class, proprietary blood test for depression ... Phase 2, National Science Foundation, Small Business Innovation ... be used to further the clinical development and ...
... review of several vendors, the University of California ... services of Velos and its flagship product, Velos eResearch. ... UCLA,s Jonsson Comprehensive Cancer Center and an affiliated clinical ... in place to deploy the system in non-cancer studies ...
Cached Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... October 22, 2014 Healthcare professionals ... their continuing education at home or on-the-go via ... to 20 brand new, premium Seminar-on-Demand CE courses. ... of over 2,000 hours of CE ... their educational experience. With such a diverse library, ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... LOS ANGELES, Sept. 12 The Lupus Foundation,of America ... Jada Smith,Family Foundation is set to host the first ... at the historic El Rey Theatre in,Los Angeles on ... and funds for lupus. Butterflies Over Hollywood will ...
... TORONTO, Sept. 12 /PRNewswire-FirstCall/ - Transition Therapeutics ... a product-focused,biopharmaceutical company developing therapeutics for disease ... results for the year,ended June 30, 2007. ... fiscal 2007 and up to the date ...
... VivoMetrics(R) Inc. and the,Philadelphia Flyers of the ... incorporated the VivoChampionTrainer System into the team,s,training regimen ... use of,the VivoChampionTrainer as pre-season Training Camp kicked ... will be utilizing the VivoChampionTrainer to optimize their,players, ...
... Team Facilities Treated with the Antimicrobial Protection of the ... SportsAide(R) System from SportCoatings(TM), ... Nets are,the next team in the NBA scoring with ... from antimicrobial contamination. SportsAide is part of the ...
... Sept. 12 Children with asthma across the,country are ... annual "Living with Asthma" poster contest sponsored by the ... American Academy of,Pediatrics (AAP). More than 9 million children ... for them to understand that asthma shouldn,t,keep them from ...
... Meeting Expectations today announced,that it has been named ... the industry,s,largest and most influential full-service independent meeting ... market. Compiled by,Penton Media,s Corporate Meetings & Incentives(R) ... corporate meetings and events,industry, the CMI 25 provides ...
Cached Medicine News:Health News:The Will and Jada Smith Family Foundation and Maybelline Join Forces With the Lupus Foundation of America for a Star-studded Gala to Raise Awareness for Lupus 2Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 2Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 3Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 4Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 5Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 6Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 7Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 8Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 9Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 10Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 11Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 12Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 13Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 14Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 15Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 16Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 17Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 18Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 19Health News:Philadelphia Flyers to Use VivoChampionTrainer(TM) System to Condition and Strengthen Players 2Health News:Philadelphia Flyers to Use VivoChampionTrainer(TM) System to Condition and Strengthen Players 3Health News:New Jersey Nets Shoot Down Staph with High-Tech Defense 2Health News:Kids, How Do You Manage Your Asthma? The AAAAI and AAP announce 17th annual poster contest 2Health News:Meeting Expectations Named to First Annual 'CMI 25' List by Corporate Meetings & Incentives Magazine 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: